Demographic, Clinical, and Antibiotic Exposure Factors Associated with Carbapenem-Resistant Acinetobacter baumannii: An Eight-Year Retrospective Study
DOI:
https://doi.org/10.56127/jukeke.v5i3.3072Keywords:
Acinetobacter baumannii, antimicrobial resistance, carbapenem resistance, CRAB, carbapenem exposureAbstract
Antimicrobial resistance is a major global health challenge, and carbapenem-resistant Acinetobacter baumannii (CRAB) is of particular concern because of its high level of resistance, limited therapeutic options, and substantial burden in healthcare-associated infections. Identifying patient characteristics and antibiotic exposure associated with CRAB is essential to support effective antimicrobial stewardship and infection prevention strategies. Objective: This study aimed to analyze the association of demographic factors, including age and comorbidities, clinical diagnosis or manifestations, and a history of carbapenem use within the previous month with CRAB among clinical isolates examined at the Clinical Microbiology Laboratory, Faculty of Medicine, Universitas Indonesia, during 2017–2024. Methodology: This quantitative study employed a retrospective cross-sectional design using secondary laboratory and clinical data. Samples were selected through total sampling from patients with clinical specimens yielding A. baumannii. Descriptive analysis was used to characterize the study population, while Chi-square tests were applied to assess associations between the investigated factors and carbapenem resistance. Findings: A total of 172 A. baumannii clinical cultures were identified, of which 118 (68.6%) were CRAB. Age was significantly associated with CRAB (p=0.004), with patients aged >59 years representing the largest CRAB group. Clinical diagnosis or manifestation was also significantly associated with CRAB (p=0.005), with respiratory tract infection being the most frequent manifestation. Previous carbapenem use within one month was significantly associated with CRAB (p=0.009), with an odds ratio of 8.33 (95% CI: 1.48–46.94). In contrast, comorbidity was not significantly associated with CRAB (p=0.665). Implications: These findings support strengthening antimicrobial stewardship, particularly the appropriate use and continuous evaluation of carbapenem therapy, alongside enhanced surveillance and infection prevention measures among high-risk patients. Originality: This study provides local epidemiological evidence from an eight-year clinical dataset and integrates demographic, clinical, and previous carbapenem-exposure factors to characterize CRAB at a clinical microbiology laboratory in Jakarta, thereby contributing institution-specific evidence for CRAB surveillance and prevention strategies.
References
Chusri, S., Silpapojakul, K., McNeil, E., Singkhamanan, K., & Chongsuvivatwong, V. (2015). Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: A case control study. Journal of Infection and Chemotherapy, 21(2), 90-95.
Collaborators, G. B. D. A. R. (2024). Global burden of bacterial antimicrobial resistance 1990-2021: A systematic analysis with forecasts to 2050. The Lancet, 404(10459), 1199-1226.
Du, X., Xu, X., Yao, J., Deng, K., Chen, S., & Shen, Z. (2019). Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. American Journal of Infection Control, 47(9), 1140-1145.
Ferlicolak, L., Altintas, N. D., & Yoruk, F. (2024). A retrospective analysis of carbapenem-resistant Acinetobacter baumannii infections in critically ill patients: Experience at a tertiary-care teaching hospital ICU. Journal of Intensive Medicine, 4(2), 181-186.
Handayani, R. S., Siahaan, S., & Herman, M. J. (2018). Antimicrobial resistance and its control policy implementation in hospital in Indonesia. Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan, 131-140.
He, X., Tang, J., He, S., & Huang, X. (2024). Analysis of risk factors and different treatments for infections caused by carbapenem-resistant Acinetobacter baumannii in Shaanxi, China. BMC Infectious Diseases, 24(1), 1130.
Jiang, Y., Ding, Y., Wei, Y., Jian, C., Liu, J., & Zeng, Z. (2022). Carbapenem-resistant Acinetobacter baumannii: A challenge in the intensive care unit. Frontiers in Microbiology, 13, 1045206.
Kao, H. H., Peng, C. K., Sheu, C. C., Lin, Y. C., Chan, M. C., & Wang, S. H. (2023). Mortality and ventilator dependence in critically ill patients with ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Journal of Microbiology, Immunology and Infection, 56(4), 822-832.
Lee, K. H., Kim, J., Lee, J. A., Kim, C. H., Kwon, O. M., & You, E. J. (2024). Carbapenem-resistant Acinetobacter baumannii outbreak in a COVID-19 isolation ward and successful outbreak control with infection control measures. Infection & Chemotherapy, 56(2), 222.
Lestari, Y. E., Andrajati, R., & Nusatia, A. C. M. (2020). Hubungan kejadian infeksi carbapenem resistant Acinetobacter baumannii dengan penggunaan antibiotika golongan karbapenem pada pasien di Rumah Sakit St. Carolus. Indonesian Journal of Clinical Pharmacy, 9(3), 189.
Marsudi, A. (2022). Tingkat pengetahuan dan perilaku masyarakat terhadap penggunaan antibiotik di beberapa apotek di Kota Ternate. Pharmacy Medical Journal, 4(2), 54.
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., & Gray, A. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629-655.
Thimmappa, P. Y., Vasishta, S., Ganesh, K., Nair, A. S., & Joshi, M. B. (2023). Neutrophil dysfunction due to altered immuno-metabolic axis in type 2 diabetes: Implications in combating infections. Human Cell, 36(4), 1265-1282.
Wang, S. H., Yang, K. Y., Sheu, C. C., Lin, Y. C., Chan, M. C., & Feng, J. Y. (2023). The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter baumannii-associated pneumonia in intensive care unit: A multicenter observational study. Scientific Reports, 13(1), 140.
World Health, O. (2024). WHO bacterial priority pathogens list 2024: Bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance.
Xiao, T., Guo, Q., Zhou, Y., Shen, P., Wang, Y., & Fang, Q. (2022). Comparative respiratory tract microbiome between carbapenem-resistant Acinetobacter baumannii colonization and ventilator-associated pneumonia. Frontiers in Microbiology, 13, 782210.
Zhang, Y., Xu, G., Miao, F., Huang, W., Wang, H., & Wang, X. (2023). Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant Acinetobacter baumannii infections in critically ill children. Frontiers in Public Health, 11, 1282413.
